Nephrotoxicity of Potential Therapeutic Agents for COVID-19 Infection with Acute Kidney Injury
- VernacularTitle: 新型冠状病毒肺炎合并急性肾损伤潜在治疗药物的肾毒性
- Author:
Ruo-Ming LI
1
Author Information
- Publication Type:Journal Article
- Keywords: Acute kidney injury; Antiviral drug; COVID-19; Nephrotoxicity
- From: Chinese Pharmaceutical Journal 2020;55(18):1481-1486
- CountryChina
- Language:Chinese
- Abstract: Since the outbreak of coronavirus disease 2019 (COVID-19), the National Health Commission and the expert group of the army have formulated multiple versions of diagnosis and treatment scheme, and drug therapy regimens have become a research hotspot for scholars. Meanwhile, some clinicians found that acute kidney injury (AKI) was an important risk factor in the death of patients with severe COVID 19. The mechanism of AKI in COVID-19 patients is still unclear and the causes may be related to virus infection or drug toxicity. Drug-related AKI directly affects the clinical treatment options and the patient's long-term prognosis. This article targets interferon-α, lopinavir / ritonavir, ribavirin, chloroquine phosphate, abidol and tocilizumab. This article reviewed potential novel coronavirus pneumonia treatment-related AKI, characteristics of the clinical cases, and mechanisms of renal toxicity, to provide a reference for clinical treatment.
